The lives of 22,000 people could have been saved if the FDA removed Bayer’s Trasylol two years ago, when his study revealed a growing number of deaths linked to the heart drug. That’s what Dennis Mangano, founder of the non-profit Ischemia Research and Educational Foundation, tells 60 Minutes in an interview to be broadcast this weekend, according to CBS News.
Mangano, whose January 2006 study in The New England Journal of Medicine showed Trasylol put patients at higher risk of heart attacks, stroke and renal failure, repeats allegations that Bayer failed to tell the FDA about negative results of their own study. Despite his study, an FDA panel declared Trasylol, a drug used to reduce bleeding during bypass procedures, was safe and effective, and voted unanimously to keep the med on the market. (Mangano is pictured to the right).
Discuss Add this link to... Bury
Mangano, whose January 2006 study in The New England Journal of Medicine showed Trasylol put patients at higher risk of heart attacks, stroke and renal failure, repeats allegations that Bayer failed to tell the FDA about negative results of their own study. Despite his study, an FDA panel declared Trasylol, a drug used to reduce bleeding during bypass procedures, was safe and effective, and voted unanimously to keep the med on the market. (Mangano is pictured to the right).
Discuss Add this link to... Bury
Comments